VKTX - Viking Therapeutics, Inc.
| Previous Close | 7.27 |
| Open | 7.26 |
| Bid | 7.00 x 1400 |
| Ask | 6.90 x 1400 |
| Day's Range | 6.58 - 7.35 |
| 52 Week Range | 6.53 - 19.74 |
| Volume | 9,199,147 |
| Avg. Volume | 1,382,200 |
| Market Cap | 494.643M |
| Beta (3Y Monthly) | 2.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.35 |
| Earnings Date | Nov 9, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.30 |
- Motley Fool
Better Buy: Intercept Pharmaceuticals vs. Viking Therapeutics
The biotech rivals each aim to dominate the treatment market for non-alcoholic steatohepatitis (NASH).
- PR Newswire
Viking Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO , Aug. 28, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
- Motley Fool
3 Top Small-Cap Stocks to Buy in August
These small-cap stocks hold the potential to deliver big-time returns.
- Motley Fool
Is Viking Therapeutics a Buy?
What you need to know about this high-risk, high-reward biotech stock.
- Thomson Reuters StreetEvents
Edited Transcript of VKTX earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Viking Therapeutics Inc Earnings Call
Motley FoolViking Therapeutics Inc (VKTX) Q2 2019 Earnings Call Transcript
VKTX earnings call for the period ending June 30, 2019.
- Motley Fool
Where Will Viking Therapeutics Be in 1 Year?
It's one of the more promising companies in the race to develop a successful NASH treatment. Will patient investors be rewarded?
- Zacks Small Cap Research
VKTX: Awaiting Feedback from FDA regarding pre-IND submission; Phase 2b trial in NASH expected to initiate 2H19…
Viking Therapeutics, Inc. (VKTX) is currently preparing for the initiation of a Phase 2b clinical trial of VK2809, the company’s thyroid beta receptor (TRβ) agonist, for the treatment of nonalcoholic steatohepatitis (NASH). The company has submitted a pre-IND briefing package to the FDA and is currently awaiting written feedback.
- PR Newswire
Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today - Preparation for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Underway; Expect to Commence Enrollment in 2H19 - Continued Progress with VK0214 for ...
- Schaeffer's Investment Research
Options Traders Load Up On VKTX Calls Ahead of Earnings
Spread activity is detected today in VKTX's options pits
- PR Newswire
Viking Therapeutics to Report Financial Results for Second Quarter 2019 on August 1, 2019
Conference Call Scheduled for Thursday, August 1 at 4:30 p.m. Eastern Time SAN DIEGO , July 25, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
- Insider Monkey
Here’s What Hedge Funds Think About Viking Therapeutics, Inc. (VKTX)
Is Viking Therapeutics, Inc. (NASDAQ:VKTX) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
- Market Realist
How Viking Therapeutics Is Positioned
Viking Therapeutics (VKTX) stock closed at $7.98 on June 12, 2.70% higher than its previous close, 14.49% above its 52-week low of $6.97, and 66.75% below its 52-week high of $24.
- Market Realist
What Analysts Recommend for CBAY and VKTX
This year, CymaBay Therapeutics (CBAY) has fallen 21.60% and Viking Therapeutics (VKTX) has risen 4.31%. While both clinical-stage companies focus on advancing their nonalcoholic steatohepatitis research and development programs, Viking seems to be ahead, considering its successful Phase 2 trials.
- Motley Fool
3 Stocks to Buy and Hold for the Next 50 Years
The catalysts these companies enjoy could translate into big returns for shareholders in the coming decades.
- Motley Fool
3 Small-Cap Biotech Stocks You Can Buy Right Now
They're risky. You'll have to wait years before any significant revenue comes in. But these biotech stocks could be huge winners.
- Simply Wall St.
Have Insiders Been Buying Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
- Insider Monkey
Were Hedge Funds Right About Dumping Viking Therapeutics, Inc. (VKTX) ?
We can judge whether Viking Therapeutics, Inc. (NASDAQ:VKTX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best […]
- Thomson Reuters StreetEvents
Edited Transcript of VKTX earnings conference call or presentation 2-May-19 8:30pm GMT
Q1 2019 Viking Therapeutics Inc Earnings Call
- Motley Fool
3 Top Biotech Stocks to Buy in May
These three biotech stocks could be prime comeback candidates.
- Zacks Small Cap Research
VKTX: Pre-IND Meeting with FDA in Summer 2019; Phase 2b NASH Trial to Initiate 2H19…
Viking Therapeutics, Inc. (VKTX) is currently preparing for the initiation of a Phase 2b clinical trial of VK2809, the company’s thyroid beta receptor (TRβ) agonist, for the treatment of nonalcoholic steatohepatitis (NASH). While details of the trial have yet to finalized, we do anticipate the trial including biopsy-confirmed NASH patients with F2 and F3 fibrosis (although there are likely to be a small number with F1 fibrosis). Regarding the upcoming trial, based on the length for competitors Phase 2b trials we estimate that if started in the second half of 2019 topline data would probably be available in the first half of 2021, although 4Q20 isn’t out of the question.
Motley FoolViking Therapeutics Inc (VKTX) Q1 2019 Earnings Call Transcript
VKTX earnings call for the period ending March 31, 2019.
- PR Newswire
Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today - New Data from Phase 2 Study of VK2809 Presented at EASL 2019; Results Demonstrate Robust Efficacy at Doses as Low as 5 mg Daily - Phase 2b Study of VK2809 ...
